OSI reiterated at buy

Merrill Lynch analyst Eric Ende reiterated OSI Pharmaceuticals, Inc. at a buy with a $40 target, believing there is an upside to ex-U.S. Tarceva sales projections after Roche makes its report. The analyst is projecting sales of $52 million to $53 million, ahead of consensus of about $48 million. Shares of the Melville, N.Y.-based pharmaceutical company were up $1.43, or 4.64%, at $32.23 on volume of 952,122 shares versus the three-month running average of 1,169,570 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.